An Open Label Multicenter, Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma With BRAFv600 Mutated and CDKN2A Loss and Expression of Rb and Treated by Vemurafenib

Trial Profile

An Open Label Multicenter, Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma With BRAFv600 Mutated and CDKN2A Loss and Expression of Rb and Treated by Vemurafenib

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2015

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms OPTIMUM
  • Most Recent Events

    • 17 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Aug 2017 to 1 Aug 2018.
    • 17 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016.
    • 04 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top